Evidence map›Paper›PMID 41982700›Full record

ArticleTranslational lung cancer research2026

Development of a deep learning model based on computed tomography automatic segmentation to assist in selecting optimal time-to-surgery and dissected lymph node count for non-small cell lung cancer patients undergoing neoadjuvant immunotherapy and chemotherapy: a multicenter study.

Junfeng Zhao, Ying Li, Jiaxuan Chen, Chuankun Han, Yifei Yan, Chen Zhou, Yingrui Bai, Yali Xu, Yintao Li

Abstract read
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Junfeng Zhao *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Ying Li *Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jiaxuan ChenShandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China.
Chuankun HanShandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China.
Yifei YanShandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China.
Chen ZhouShandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China.
Yingrui BaiSchool of Clinical Medicine, Shandong Second Medical University, Weifang, China.
Yali Xu *Department of Pathology, Shandong Provincial Hospital Affiliated with Shandong First Medical University, Jinan, China.
Yintao LiDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Many studies have confirmed the efficacy of neoadjuvant immunotherapy combined with chemotherapy (NICT) in treating patients with non-small cell lung cancer (NSCLC). However, the optimal time-to-surgery (TTS) and the appropriate dissected lymph node (DLN) count remain unclear. Therefore, this study aims to determine the optimal TTS and DLN count for NSCLC following NICT by establishing a deep learning model based on computed tomography (CT) automatic segmentation to predict the efficacy of neoadjuvant therapy. Methods: We retrospectively analyzed patients with NSCLC who underwent NICT and surgical treatment at two centers between January 2019 and June 2024. A proven high-precision and strong generalization three-dimensional (3D) segmentation architecture with a flexible interaction mode (VISTA3D) is applied in this study for CT images to achieve automatic tumor identification in NSCLC patients via automated segmentation combined with segmentation point prompts. This study employed ResNet18 (an 18-layer residual network pre-trained on ImageNet) as the feature extraction backbone. In the final configuration, the shallow stagelayers of the model were frozen, with only the two deeper stagelayers unfrozen to participate in gradient updates. This study employed BCEWithLogitsLoss to accommodate the classification requirements of the task. The primary evaluation metric in this study was the receiver operating characteristic curve. Based on the model, patients were divided into two groups: responders and non-responders. Optimal TTS and DLN counts were determined for each group. Results: A total of 330 patients were included, with 270 patients in the training set and 60 patients in the external test set. The area under the curve of the deep learning model was 0.854 (95% confidence interval: 0.745-0.976). We assigned patients to responders and non-responders groups based on the deep learning model score. In the responder group, prolonged TTS was associated with better prognosis, with no significant difference in postoperative complications. In the non-responder group, earlier surgery was associated with better prognosis, with no significant difference in postoperative complications. In the responder group, a DLN count of ≤21 was associated with better prognosis. Conclusions: In patients undergoing NICT, our model-based stratification suggests that for predicted responders, appropriately delaying surgery may be associated with better outcomes, whereas for predicted non-responders, earlier surgery is associated with better outcomes. Furthermore, among predicted responders, an observed DLN count of ≤21 was associated with improved survival, highlighting the potential importance of balancing oncologic resection with immune preservation. These findings require prospective validation.

Indexed as

dissected lymph node (DLN)immunotherapyneoadjuvantNon-small cell lung cancer (NSCLC)time-to-surgery (TTS)

Identifiers

PMID41982700
PMCPMC13071746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.